Elisa Petris
Director/Board Member at Quell Therapeutics Ltd.
Network origin in Elisa Petris first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Imperial College London
188
| College/University | Other Consumer Services | 188 |
London Business School
163
| College/University | Other Consumer Services | 163 |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom.
34
| Subsidiary | Investment Managers | 34 |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom.
15
| Public Company | Biotechnology | 15 |
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom.
7
| Holding Company | Pharmaceuticals: Major | 7 |
Blue Earth Diagnostics Ltd.
 Blue Earth Diagnostics Ltd. Medical/Nursing ServicesHealth Services Blue Earth Diagnostics Ltd. engages in the development and commercialization of positron emission tomography imaging agents. It focuses on the molecular imaging diagnostics. The company was founded in March 2014 and is headquartered in Oxford, the United Kingdom.
4
| Subsidiary | Medical/Nursing Services | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Elisa Petris via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Private Equity Investor | |
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal Director/Board Member | |
RA Capital Management LP
 RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Investment Managers | Analyst-Equity | |
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Founder Corporate Officer/Principal | |
| SYNCONA LIMITED | Investment Trusts/Mutual Funds | Corporate Officer/Principal Chief Executive Officer Corporate Officer/Principal Private Equity Investor Corporate Officer/Principal | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Doctorate Degree | |
| DECHRA PHARMACEUTICALS | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| College of the Holy Cross (Massachusetts) | College/University | Undergraduate Degree | |
| University of Oxford | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree Masters Business Admin Graduate Degree Doctorate Degree | |
Institute of Chartered Accountants in England & Wales
 Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services The Institute of Chartered Accountants in England & Wales ensures that its members, students, and affiliates maintain the highest standards of professional competency and conduct to protect the public interest. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. With over 150,000 members, the institute provides technical information, helplines, and communities to its members. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Cambridge | College/University | Doctorate Degree Doctorate Degree Corporate Officer/Principal Graduate Degree Doctorate Degree Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| University of London | College/University | Doctorate Degree Corporate Officer/Principal Undergraduate Degree | |
| The University of Reading | College/University | Undergraduate Degree | |
| INSEAD | College/University | Graduate Degree Masters Business Admin | |
| University of Bristol | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| University of Cape Town | College/University | Undergraduate Degree | |
| EQT Partners GmbH | Investment Managers | Private Equity Investor | |
| University College London | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Graduate Degree | |
AnaCap Financial Partners Ltd
 AnaCap Financial Partners Ltd Investment ManagersFinance AnaCap Financial Partners Ltd (AnaCap Financial Partners) is a Private Equity firm founded in 2005 by Joe Giannamore. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Public Communications Contact | |
The Royal Society of Medicine
 The Royal Society of Medicine Miscellaneous Commercial ServicesCommercial Services The Royal Society of Medicine provides postgraduate medical education. The Society provides a range of educational activities and opportunities for doctors, dentists and veterinary surgeons, including students, and for allied healthcare professionals. It also promotes an exchange of information and ideas on the science, practice and organization of medicine, both within the health professions and with responsible and informed public opinion. The Society was founded in 1805 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| King's College London | College/University | Undergraduate Degree Corporate Officer/Principal | |
Bird Rock Bio, Inc.
 Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Biotechnology | Director/Board Member Director/Board Member | |
GE UK Group
 GE UK Group MiscellaneousMiscellaneous Part of GE Aerospace, GE UK Group is an investment holding company. GE UK Group is based in Altrincham, UK. The British company was founded in 2008. The CEO is Kevin Michael O'Neill. | Miscellaneous | Corporate Officer/Principal | |
| JAZZ PHARMACEUTICALS PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| UCL Cancer Institute Research Trust | Corporate Officer/Principal | ||
University College London Hospitals NHS Foundation Trust
 University College London Hospitals NHS Foundation Trust Hospital/Nursing ManagementHealth Services University College London Hospitals NHS Foundation Trust provides first-class acute and specialist services in six hospitals in central London, UK. The British company's mission is to deliver top-quality patient care, excellent education, and world-class research. The company also offers events, classes, and workshops at the Macmillan Support and Information Service (MSIS) and an audiological service for GPs who would like to refer patients for age-related audiological assessments. Additionally, the company provides information about the sarcoma service and hearing therapists who work with adults who have hearing loss and associated disorders, such as tinnitus and hyperacusis, and other forms of hypersensitivity. The company is ultimately controlled by the Government of United Kingdom. | Hospital/Nursing Management | Corporate Officer/Principal | |
| Columbia Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| Oxford University Medical School | College/University | Undergraduate Degree | |
Autolus Ltd.
 Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Biotechnology | Chairman Chief Executive Officer | |
OMass Therapeutics Ltd.
 OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services OMass Therapeutics Ltd. develops native mass spectrometry platform The company was founded by Dame Carol Robinson and is headquartered in Oxford, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| NIGHTSTAR THERAPEUTICS PLC | Pharmaceuticals: Major | Chairman Director/Board Member | |
| POLAREAN IMAGING PLC | Medical Specialties | Director/Board Member Chairman | |
| AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member Director/Board Member | |
Azeria Therapeutics Ltd.
 Azeria Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Azeria Therapeutics Ltd. engages in the research and development of pharmaceutical products. It develops treatments for hormone resistance that targets breast and prostate cancer patients. The company was founded by Jason Carroll in 2017 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| 89BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
Anaveon AG
 Anaveon AG BiotechnologyHealth Technology Anaveon AG engages in the development of immune therapies against cancer. Its compounds promote effector T-cell functions to enhance a patient?s immune system to respond to tumors. The company was founded on December 11, 2017 by Onur Boyman and Andreas Katopodis and is headquartered in Bottmingen, Switzerland. | Biotechnology | Chairman Director/Board Member | |
| WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
McKinsey & Company Holdings Ltd.
 McKinsey & Company Holdings Ltd. Financial ConglomeratesFinance Part of McKinsey & Co., Inc., McKinsey & Company Holdings Ltd. is a consulting firm that partners with leaders on strategy, innovating to net zero, leading with tech, and building capabilities for a sustainable, inclusive, growing future. The company is based in London, UK. The British company specializes in Consumer Packaged Goods and has conducted research, articles, and reports on the changes that matter most for the challenges and opportunities ahead. The company was founded in 2011 by Brian K. Stafford. | Financial Conglomerates | Corporate Officer/Principal | |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor | |
Canbridge Pharmaceuticals, Inc. (United States)
 Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Biotechnology | Director/Board Member | |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Biotechnology | Chairman Chairman Director/Board Member | |
| ITEOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| EQT Partners SAS | Investment Managers | Private Equity Investor | |
Resolution Therapeutics Ltd.
 Resolution Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Resolution Therapeutics Ltd. operates as a macrophage cell therapy company. The company was founded on December 14, 2017 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Chairman | |
Purespring Therapeutics Ltd.
 Purespring Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Purespring Therapeutics Ltd. provides biotechnological research and experimental development services. The company was founded on April 1, 2020 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
| CONNECT BIOPHARMA HOLDINGS LIMITED | Pharmaceuticals: Major | Director/Board Member | |
| ACHILLES THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Director/Board Member Chief Executive Officer Founder Director/Board Member | |
| Forcefield Therapeutics Ltd. | Chairman Chief Executive Officer Director/Board Member |
Statistics
International
| United Kingdom | 29 |
| United States | 15 |
| France | 3 |
| Germany | 3 |
| South Africa | 2 |
Sectoral
| Health Technology | 20 |
| Consumer Services | 15 |
| Finance | 7 |
| Commercial Services | 6 |
| Miscellaneous | 3 |
Operational
| Director/Board Member | 300 |
| Corporate Officer/Principal | 120 |
| Private Equity Investor | 86 |
| Chairman | 80 |
| Undergraduate Degree | 71 |
Most connected contacts
| Insiders | |
|---|---|
| Murugappan Muthiah Murugappan | 54 |
| Edwin Moses | 35 |
| Martin Murphy | 33 |
| Ken Galbraith | 30 |
| Roel Bulthuis | 29 |
| Bryan Geoffrey Morton | 22 |
| Jamil Akbar | 22 |
| Cyrille Yann Nicolas Petit | 18 |
| Chris Hollowood | 18 |
| Derek DiRocco | 17 |
| Yi Ke Guo | 16 |
| Carsten Boess | 15 |
| Mohammed Alzubi | 15 |
| Hitesh Thakrar | 14 |
| Justin Stebbins | 13 |
- Stock Market
- Insiders
- Elisa Petris
- Company connections
